Delivery Order SPE2DB22D1041-SPE2DB25FUBH4
- Not listed
- The Defense Logistics Agency awarded a $2,015.65 delivery order to AmerisourceBergen Drug Corp for Trulicity 4.5 mg/0.5 ml pen (0.5 ml), a diabetes medication, on August 8, 2025, with completion expected by August 11, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order was competitively awarded and represents a child contract under AmerisourceBergen's larger relationship with the federal...
- The Defense Logistics Agency awarded a $1,351.35 delivery order to AmerisourceBergen Drug Corp for Trulicity 3 mg/0.5 mL pens on August 1, 2025, with completion targeted for August 4, 2025. This firm fixed price, competitively awarded contract involves the supply of the diabetes medication from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award carries no set-aside designation and represents a child order under AmerisourceBergen's larger contract vehicle with the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $4,222.19 to AmerisourceBergen Drug Corp for the supply of Trulicity 1.5 mg/0.5 mL pens on August 11, 2025, with completion scheduled for August 12, 2025. This firm fixed-price delivery order represents a pediatric diabetes medication procurement supporting federal healthcare requirements. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,951.95 for Trulicity 1.5 mg/0.5 ml pen (0.5 ml), a diabetes medication. The contract was awarded on August 15, 2025, with an ultimate completion date of August 18, 2025, and represents a firm fixed-price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Trulicity 1.5 mg/0.5 mL pens valued at $5,044.48. This firm fixed-price delivery order, which is set to be completed by July 30, 2025, represents a pediatric diabetes medication procurement for federal healthcare systems. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,663.27 for Trulicity 1.5 mg/0.5 ml pen 0.5ml, a diabetes medication, with an ultimate completion date of August 13, 2025. This non-competitive, firm fixed-price delivery order was awarded on August 12, 2025, with performance to be executed at the vendor's location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's broader pharmaceutical supply...
- The U.S. Defense Department's Medical Supply Chain awarded a $12,012 delivery order to AmerisourceBergen Drug Corp for the supply of Trulicity 1.5 mg/0.5 mL pens on July 22, 2025, with completion scheduled for July 23, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with the Defense Logistics Agency Troop Support Medical (SPE2DX), a $999.999 billion vehicle extending through...
- The Defense Logistics Agency awarded a $1,383.93 delivery order to AmerisourceBergen Drug Corp for Trulicity 1.5 mg/0.5 mL pens on August 1, 2025, with completion expected by August 4, 2025. This firm fixed-price contract, issued without set-aside designation, leverages AmerisourceBergen's established relationship with DLA through competitive procurement procedures. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency awarded a delivery order valued at $9,309.30 to AmerisourceBergen Drug Corp for the supply of Trulicity 4.5 mg/0.5 mL pens with a completion date of July 29, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's distribution center in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,545.30 for Trulicity 1.5 mg/0.5 ml pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value pharmaceutical transaction under AmerisourceBergen's broader federal contract portfolio. The product will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery...
- SPE2DB22D1041Indefinite Delivery Contract
- SPE2DB22D1041-SPE2DB25FUBH4Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,466.03 to AmerisourceBergen Drug Corp for the supply of Trulicity 4.5 mg/0.5 mL pens on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed price delivery order represents a pediatric diabetes medication supply for military healthcare systems. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle enables AmerisourceBergen to serve as a comprehensive pharmaceutical supplier to military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. The broader IDC encompasses specialty medications, brand-name and generic drugs, vaccines, and various medical supplies across multiple therapeutic domains, with DLA planning to establish Pharmaceutical Prime Vendor Global Program Generation V contracts through multiple regional awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 8/4/25 |